Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 45

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 1
Chunk 45
---
012 (9,263)(184.8)%Interest income2,944 3,144 (200)(6.4)%Changes in fair value of trading securities1,185 — 1,185 NAInterest expense(21)(270)249 92.2 %(Loss) income before income taxes(143)7,886 (8,029)(101.8)%Income tax benefit(4,666)(1,034)(3,632)(351.3)%Net income$4,523 $8,920 $(4,397)(49.3)%

NA = Not applicable

The following table indicates the amount of stock-based compensation expense (non-cash) reflected in the line items above (in thousands):

Three Months EndedJune 30,20252024Change(unaudited)Cost of sales (exclusive of amortization of acquired intangible assets)$1,422 $1,401 $21 Research and development1,962 2,637 (675)Selling, general and administrative7,824 9,141 (1,317)Total stock-based compensation expense$11,208 $13,179 $(1,971)

34

The following table provides a disaggregation of net revenues by type (in thousands):

Three Months EndedJune 30,20252024Change(unaudited)Dermatologic(1)$56,297 $68,828 $(12,531)Non-Dermatologic(2)29,891 18,174 11,717 Total net revenues$86,188 $87,002 $(814)

(1)Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic GEP offering.

(2)Consists of TissueCypher, DecisionDx-UM and IDgenetix. 

The following table presents the calculation of gross margin (in thousands, except percentages):

 Three Months EndedJune 30, 20252024Change(unaudited)Net revenues$86,188 $87,002 $(814)Less: Cost of sales (exclusive of amortization of acquired intangible assets)17,626 14,519 3,107 Less: Amortization of acquired intangible assets1,961 2,247 (286)Gross margin$66,601 $70,236 $(3,635)Gross margin percentage77.3 %